1 / 93

Antianginal Agents and Hypotensive Agents

Antianginal Agents and Hypotensive Agents. 馬偕紀念醫院藥劑室 林育成藥師. Amlodipine besylate (Norvasc). Form: Tab: 5mg Dosage: Hypertension: Initial 2.5-5mg qd, MD 5-10mg qd, Max. 10mg/day Angina: 5-10mg qd, MD 10mg qd. Amlodipine besylate (Norvasc). Precautions aortic stenosis CHF

tiana
Télécharger la présentation

Antianginal Agents and Hypotensive Agents

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antianginal Agents and Hypotensive Agents 馬偕紀念醫院藥劑室 林育成藥師

  2. Amlodipine besylate (Norvasc) • Form: Tab:5mg • Dosage: • Hypertension: Initial 2.5-5mg qd, MD 5-10mg qd, Max. 10mg/day • Angina: 5-10mg qd, MD 10mg qd

  3. Amlodipine besylate (Norvasc) • Precautions • aortic stenosis • CHF • exacerbation of angina during initiation of therapy, after dose increases, or withdrawal of beta blocker therapy • hypotension (initially or after dose increases) • liver impairment • persistent progressive dermatologic reactions

  4. Amlodipine besylate (Norvasc) • Dose adjustments: • renal impairment: NOT recommended in patients with severe renal impairment (CrCl below 30 mL/min/1.73m(2), serum creatinine >/=3 mg/dL) • liver disease: starting dose, 2.5 mg/10 mg • geriatrics: starting dose, 2.5 mg/10 mg

  5. Isosorbide dinitrate (Isordil, Sorbitrate tab, Isoket inj) • Dose: • Oral, initial 5-20 mg q6h, MD 10-40mg q6h ac, • IV infusion, 2-7mg/hr, up to 10mg/hr • Note: • Dosing interval may be bid or tid and last dose no later than 7 PM to minimize nitrate tolerance

  6. Isosorbide mononitrate (Imdur CR) • Form: Tab: 60mg (extended release) • Dose: • Initial 30mg qd for 2-4 days then 60-120 mg qd • Note: • should be taken in the morning • should be swallowed whole not chewed, but it can be administered half of a tablet at a time

  7. Isosorbide monotrate (ISMO-20, Isormol) • Form: Tab:20mg • Dose: • Initial 10mg bid for 2 days then 20-30mg bid • Note: • Asymmetrical dosing regimen of 7AM and 3PM or 9AM and 5PM to allow for a nitrate-free dosing interval to minimize nitrate tolerance • Do not crushor chew but can cut half

  8. Isosorbide monotrate (ISMO-20, Isormol) • Administration: • administer 0.5 hr before or 1 hr after meals • do not crushor chew extended release dosage forms • dose to provide a 10-12 hr drug-free interval

  9. Drug-drug interaction:Organic nitrate and Sildenafil (Viagra) • SILDENAFIL inhibits phosphodiesterase type 5 (PDE5) which is responsible for the metabolic degradation of cyclic guanosine monophosphate (cGMP). • Organic nitrates exert their action by activation of guanylate cyclase, which increases cGMP. Because of the potential for excessive hypotensive effects as a result of increased cGMP, the concomitant use of sildenafil and organic nitrates is contraindicated

  10. Diltiazem HCl (Herbesser, Cartil) • Form: Tab:30mg • Dose: • angina: start with 30mg qid ac, increase dosage gradually until optimal response, average 180-360 mg/ day divide into 3-4 doses

  11. Diltiazem HCl (Diltelan SR) • Form: Cap: 90mg (controlled release) • Dose: Initial 90mg bid for 2 wks, may increase gradually to 360mg/day div. into 2 dose • Hypertension: 240-360mg/day • Angina: 240mg/day • Note: Swallow whole; do not open, chew or crush the capsules

  12. Nicorandil (Sigmart) • Form: Tab:5mg • Dose: 5-20 mg bid, Max. 30mg bid

  13. Mechanism of Nicorandil (Sigmart) • Nicorandil : potassium channel openers or activators, which produce vascular smooth muscle relaxation by increasing potassium flux through adenosine triphosphate (ATP)-sensitive sarcolemmal potassium channels • This leads to hyperpolarization of the cell membrane, and subsequent decreases in levels ofcytoplasmic calcium (calcium channel blockade) and dilation of arterial resistance vessels

  14. Nifedipine (Adalat OROS) • Form: Tab:30 mg (extended release) • Dose: initial 30mg once daily, may be increased to 120mg once daily if needed • Note: Swallow whole; do not crush or chew

  15. Nitroglycerin (Glyceryl trinitrate, NTG, Nitrostat tab, Tridil inj) • Form: Tab:0.6mg, inj:50 mg/10ml amp • Dose: • Sublingal, 0.2-0.6mg every 5 min for max. of 3 doses in 15 min • IV infusion, initial 5mcg/min then increased by 5mcg/min at 3-5 min intervals until a response is noted or the rate is 20mcg/min

  16. Nitroglycerin lingual aerosol • Form: Aerosol: 0.4mg/spray, 200 sprays/set • Dose: • Acute relief of angina pectoris: 1-2 srpays (0.4-0.8mg) every 3-5min if necessary , Max. of 3 doses in 15 min • Prophylaxis angina pectoris: 1-2 sprays, 5-10min before situations

  17. Antiadrenergic agents-centrally acting • Clonindine HCl (Catapres) • Methyldopa (Aldomet)

  18. Captopril (Capoten) • Form: Tab:25mg • Dose: Hypertension : Initial mg bid-tid ac, the dosage being increased to 50mg bid-tid if necessary after 1 or 2 wksCHF: Initial 25mg tid ac, the dosage being increased up to 50mg tid; if further increased in dosage, it is made after an interval of 2 wks, MD 50-100mg bid-tid, Max. 450mg/day

  19. Cotraindication of Capoten • A. Angioedema induced by other angiotensin converting enzyme (ACE) inhibitors during prior exposure • B. Anuric renal failure during prior exposure to ACE inhibitors • C. Hypersensitivity to this or any other ACE inhibitor • D. Hereditary or idiopathic angioedema • E. Pregnancy (second and third trimesters particularly

  20. Enalapril maleate (Renitec) • Form: Tab:20mg • Dose: • Hypertension: Initial 2.5~5mg/day, MD 10-40mg/day divide into 1-2 doses • CHF: initial 2.5mg qd-bid, MD 5-20mg/day divide into 1-2 doses, Max. 40mg/day

  21. Enalapril maleate (Renitec) • MECHANISM : • Enalapril is a weak angiotensin-converting enzyme inhibitor; however, hepatic activation of enalapril to enalaprilat being 10 to 20 times as potent as captopril

  22. Enalapril maleate (Renitec) • Precautions: • ACE-inhibitor induced angioedema • apheresis (low-density lipoprotein) with dextran sulfate • CHF, severe (oliguria and/or progressive azotemia may occur)

  23. Fosinopril Sodium (Monopril) • Form: Tab: 10mg • Hypertension: initial 10mg qd, MD 20~40mg/day qd or bid up to 80mg/day • CHF: initial 10mg qd, MD 20~40mg/day

  24. Fosinopril Sodium (Monopril) • Mechanism : • Fosinopril is a prodrug and must undergo reesterification to its biologically active diacid metabolite, fosinoprilat. Fosinopril has a phosphinic acid binding site and lacks the sulfhydryl group characteristic of captopril

  25. Fosinopril Sodium (Monopril) • Precautions • ACE-inhibitor induced angioedema • apheresis (low-density lipoprotein) with dextran sulfate • CHF, severe (oliguria and/or progressive azotemia may occur) • collagen vascular disease, especially in presence of renal impairment (risk of neutropenia, agranulocytosis)

  26. Perindopril tert-butylamine (Acertil) • Form: Tab: 4mg • Dose: • Hypertenision: Initial 2mg qd, MD 4mg/day, Max. 8mg/day, Max. 8mg/day acCHF: Initial 2mg qd, MD 4mg/day ac

  27. Perindopril tert-butylamine (Acertil) • Mechanism: • Perindopril is an ester prodrug, requiring in vivo hydrolysis to its active diacid metabolite, perindoprilat • Perindoprilat is a long-acting, non-thiol angiotensin converting enzyme (ACE) inhibitor

  28. Rampril (Tritace) • Form: Cap: 2.5mg • Dose:Hypertension: initial 1.25-2.5mg qd, MD 2.5-5mg as a single dosage or in 2 divided doses. Max. 10mg/dayCHF post-MI: initial 2.5mg bid, if hypotension occurs,dosage should be reduced to 1.25mg bid. MD 5mg bid

  29. Rampril (Tritace) • Mechanism : • Ramipril is a prodrug that undergoes enzymatic saponification by esterases in the liver to its biologically active metabolite, ramiprilat. Ramipril is a long active angiotensin converting enzyme inhibitor with hypotensive effects lasting a full 24 hours with single daily dosing.

  30. Clonidine (Catapres) • Form: Tab:75mcg • Dose: • Initial 0.05-0.1mg bid, may be increase by 0.1-0.2 mg/day, • MD 0.2-1.2mg/day divide into 2-4 doses, • Max. 2.4mg/day

  31. Methyldopa (Aldomet) • Form: Tab:250mg • Dose: • Initial 250mg bid-tid for 2 days then being adjusted until the desired response is obtained, • MD 500mg-2g/day divide into 2-4 doses

  32. Indication: Benign prostatic hyperplasia Form: Tab:10mg (prolonged release) Alfuzosin HCl (Xatral XL)

  33. Alfuzosin HCl (Xatral XL) • A. Alfuzosin: a selective -1 adrenoceptor antagonist. • B. dosing information: • benign prostatic hyperplasia :7.5 to 10 mg daily; • hypertension, 5 to 10 mg twice daily. • Dose reductions are suggested in patients with liver disease, and in the elderly.

  34. Alfuzosin HCl (Xatral XL) • CONTRAINDICATIONS • A. Concomitant use of potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir) • B. Hepatic insufficiency (moderate to severe) • C. Hypersensitivity to alfuzosin or other quinazolines

  35. Alfuzosin HCl (Xatral XL) • Precautions: • A. Carcinoma of the prostate and benign prostatichyperplasia may cause the same symptoms and frequently coexist. Prostate cancer should be ruled out prior to treatment. • B. Concomitant use of other alpha-blockers • C. Congenital or acquired QT prolongation syndromes • D. Coronary artery disease

  36. Alfuzosin HCl (Xatral XL) • Precautions: • E. General anesthesia • F. Hepatic disease (mild) • G. Dizziness, lightheadedness • H. Orthostatic hypotension • I. Renal dysfunction (severe) • J. Syncope (First-dose effect)

  37. Doxazosin (Doxaben) • Indications • Benign prostatic hyperplasia • Hypertension • Form: Tab: 1mg • Dose: Initial 1mg qd, MD 2mg qd, if necessary subsequent dosage adjustments can be made by doubling the dose every 2 wks, Max. 16mg/day

  38. Doxazosin (Doxaben) • Precautions • carcinoma of the prostate • concomitant use of other antihypertensives (additive hypotensive effects) • first dose syncope/ sudden loss of consciousness • liver disease • orthostatic hypotension, syncope • recent cerebrovascular accident

  39. Doxazosin (Doxaben) • Administration • first dose phenomenon characterized by excessive postural hypotension, palpitations, syncope, and tachycardia can be minimized by limiting the initial dose to 1 mg, administering the first dose at bedtime, and increasing the dosage slowly

  40. Terazosin • Form: Tab: 2mg • Dose: • Hypertension: Initial 1mg hs, may be increased gradually to 5mg/day, Max. 20mg/day • Benign prostatic hyperplasia: Initial 1mg hs, may be increased in a stepwise manner to 2,5 and 10mg/day as necessary, Max. 20mg/day

  41. Acebutolol Hydrochloride (Sectral) • Angina: 600-1600 mg ORALLY daily (divided 2-3 times/day) • Arrhythmias: initial, 400 mg ORALLY daily (divided twice a day); maintenance, 600-1200 mg ORALLY daily (divided 2-3 times/day) • Hypertension: initial, 400 mg ORALLY daily; maintenance, 400-800 mg ORALLY daily (may be divided twice a day); MAX 1200 mg/day (divided twice a day)

  42. Acebutolol Hydrochloride (Sectral) • Dose Adjustments • geriatric: may require lower maintenance doses (specific guidelines unavailable); doses above 800 mg/day should be avoided • renal impairment: CrCl less than 50 mL/min - reduce usual adult dose by 50% • renal impairment: CrCl less than 25 mL/min - reduce usual adult dose by 75%

  43. Acebutolol Hydrochloride (Sectral) • FDA labeled indications • Arrhythmia • Hypertension • Non-FDA labeled indications • Angina pectoris

  44. Acebutolol Hydrochloride (Sectral) • Contraindications • cardiogenic shock • hypersensitivity to acebutolol • overt cardiac failure • second and third degree AV block • severe sinus bradycardia

  45. Atenolol (Tenormin) • Form: Tab: 50mg • Hypertension (HTN): 50-100 mg ORALLY once daily

  46. Atenolol (Tenormin) • Dose Adjustments: • hemodialysis: 25-50 mg after each dialysis session • renal impairment: CrCl 35 mL/min or greater - normal dosing • renal impairment: CrCl 15-35 mL/min - MAX dose 50 mg once daily • renal impairment: CrCl less than 15 mL/min - MAX dose 25 mg once daily

More Related